Altis Biosystems

Altis Biosystems is a biotechnology startup that is dedicated to "Capturing the Complexity of the Human Gut." Founded in 2015 and headquartered in the United States, Altis Biosystems aims to provide scientific innovation through collaborative relationships to help companies develop safer and more effective therapies for patients suffering from human diseases. The company's flagship product is the Repligut® Systems, which are in vitro models derived from stem cells and specifically designed for pre-clinical drug discovery. These innovative systems overcome the limitations of conventional cell lines and animal models, providing a highly accurate representation of human intestinal physiology. Altis Biosystems' RepliGut® Planar models utilize human donor intestinal stem cells to advance novel pharmaceuticals through a process of sequential proliferation and differentiation, ultimately transforming into essential cell types found in the human gastrointestinal epithelium for use in drug discovery and development. Their RepliGut® Models, accurately replicating the complex cellular lifecycle of the intestinal crypt, offer a versatile platform for various applications including compound screening, disease modeling, drug disposition analysis, toxicity assessments, efficacy studies, and fundamental research investigations. The company's last investment was a Series A round on 09 January 2024, led by the Triangle Tweener Fund. Altis Biosystems' pioneering approach not only furthers the understanding of human biology but also has the potential to significantly reduce the dependence on animal studies in the pre-clinical drug discovery landscape.